Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial

Renaud Sabatier,Frédérique Rousseau,Florence Joly,Claire Cropet,Coline Montégut, Johanna Frindte,Saverio Cinieri,Eva M Guerra Alía,Stephan Polterauer,Hiroyuki Yoshida,Ignace Vergote,Nicoletta Colombo,Sakari Hietanen,Rémi Largillier,Ulrich Canzler,Alain Gratet,Frederik Marmé,Laure Favier,Eric Pujade-Lauraine,Isabelle Ray-Coquard

European Journal of Cancer（2023）

引用 3|浏览32

暂无评分

摘要

•Older patients in PAOLA-1 had unfavourable baseline clinical and molecular features.•Benefits of olaparib plus bevacizumab were similar in older and younger patients.•Improved progression-free survival was limited to those with HRD-positive tumours.•Safety and tolerability profiles were similar in older and younger patients.

查看译文

关键词

Ovarian cancer,Elderly,Olaparib,Survival,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要